Access cutting-edge acute ischemic stroke treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access acute ischemic stroke specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related acute ischemic stroke treatment provided free
The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS. 2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS. During Part 1, participants will be randomized to JX 10 (1mg/kg
Sponsor: Corxel Pharmaceuticals
Check if you qualify for this acute ischemic stroke clinical trial in Chicago, IL
If you're searching for acute ischemic stroke treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute ischemic stroke specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.